Powderject's smaller product lines also fared well with sales of yellow fever vaccine
Arilvax up 70 per cent to pounds 3.2 million boosted by marketing.
Powderject's smaller product lines also fared well with sales of its yellow fever vaccine
Arilvax surging 70pc to pounds 3.2m boosted by increased marketing initiatives.
PHARMACEUTICAL firm Powderject has launched its yellow fever vaccine
Arilvax, made in its Speke Evans Vaccines plant, in the Netherlands after its successful UK launch last year.
The fall came after an announcement in the United States that approval of its yellow fever vaccine
Arilvax has been delayed.
OraVax will be the exclusive United States marketer and distributor of Evans Medical Limited's yellow fever vaccine
Arilvax once licensed in the United States.
Sales of TB vaccines performed well, while the yellow fever drug
Arilvax made 'good progress'.